CBER Director Marks: Regenerative Medicine Enforcement Will Be 'Notched Up' In 2018
Executive Summary
In an interview with the Pink Sheet, Marks said the guidances on regenerative medicines make clear what the agency will be enforcing.
You may also be interested in...
US FDA’s Stem Cell Clinic Enforcement Takes A Hit With Loss In California Case
Federal judge denies government’s request to permanently enjoin California stem cell clinic from administering unapproved stromal vascular stem cell treatments, concluding they are not ‘drugs’ under the FD&CA. Ruling runs counter to decision in similar case involving a Florida stem cell clinic.
US FDA’s Stem Cell Clinic Enforcement Takes A Hit With Loss In California Case
Federal judge denies government’s request to permanently enjoin California stem cell clinic from administering unapproved stromal vascular stem cell treatments, concluding they are not ‘drugs’ under the FD&CA. The ruling runs counter to a decision in a similar case involving a Florida stem cell clinic.
US FDA To Explore New Regulatory Pathways For Some Cellular Products
Agency re-evaluating criteria for certain human cells, tissues and cellular and tissue-based products (HCT/Ps) that are not ideally regulated as BLAs; industry suggests a 2014 guidance which created an alternative pathway for cord blood products could serve as potential template.